Baxter International (NYSE:BAX) Given New $21.00 Price Target at The Goldman Sachs Group

Baxter International (NYSE:BAX) had its target price lifted by The Goldman Sachs Group from $19.00 to $21.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a neutral rating on the medical instruments supplier’s stock.

BAX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Baxter International in a research note on Friday, May 15th. Barclays upped their price target on Baxter International from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Zacks Research lowered Baxter International from a “hold” rating to a “strong sell” rating in a research report on Monday. Evercore lowered their price objective on Baxter International from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Finally, TD Cowen dropped their target price on Baxter International from $22.00 to $20.00 in a report on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $19.91.

Baxter International Price Performance

BAX opened at $22.14 on Wednesday. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43. The company has a market cap of $11.44 billion, a price-to-earnings ratio of -10.40, a price-to-earnings-growth ratio of 3.52 and a beta of 0.62. The stock has a fifty day simple moving average of $20.04 and a two-hundred day simple moving average of $19.30. Baxter International has a 12-month low of $15.73 and a 12-month high of $29.35.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. The firm had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The company’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 EPS. Research analysts predict that Baxter International will post 1.91 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 1st. Shareholders of record on Friday, May 29th were paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date was Friday, May 29th. Baxter International’s dividend payout ratio (DPR) is currently -1.88%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Imprint Wealth LLC purchased a new position in Baxter International in the 3rd quarter worth about $27,000. Basepoint Wealth LLC bought a new stake in shares of Baxter International in the fourth quarter worth approximately $26,000. MUFG Securities EMEA plc purchased a new position in shares of Baxter International during the second quarter valued at approximately $46,000. Los Angeles Capital Management LLC bought a new position in Baxter International during the fourth quarter valued at approximately $46,000. Finally, Versant Capital Management Inc boosted its holdings in Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,043 shares during the last quarter. 90.19% of the stock is owned by institutional investors.

Baxter International News Roundup

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Goldman Sachs raised its price target on Baxter to $21 from $19, indicating a somewhat better outlook even though the firm kept a neutral rating. Benzinga
• Positive Sentiment: Technical coverage noted a golden cross in Baxter’s chart, which may support buying interest from traders focused on trend signals. AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
• Neutral Sentiment: Baxter announced updates to its segment reporting structure and metrics, but the headline appears mainly operational and not clearly tied to a major earnings or guidance change. Baxter International Updates Segment Reporting Structure and Metrics
• Negative Sentiment: Zacks Research cut earnings estimates across multiple periods, including FY2026, FY2027, and Q2/Q3 2026, signaling softer profit expectations for Baxter International (NYSE: BAX). Zacks.com
• Negative Sentiment: Zacks also downgraded Baxter from hold to strong sell, reinforcing a more cautious view on the stock. Zacks.com

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.